Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years -October 20, 2023 at 06:46 am EDT
First readout of two-year data from long-term extension study ...